These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12857569)

  • 81. Rare cells predict GVHD.
    Strober S; Lowsky R
    Blood; 2012 May; 119(21):4820-1. PubMed ID: 22627595
    [No Abstract]   [Full Text] [Related]  

  • 82. Cerebral toxoplasmosis in undifferentiated connective disease treated with mycophenolate mofetil: an unusual case report.
    Pistacchi M; Gioulis M; Zirillo M; Francavilla E; Zambito Marsala S
    Acta Neurol Belg; 2016 Dec; 116(4):633-636. PubMed ID: 26754114
    [No Abstract]   [Full Text] [Related]  

  • 83. Mycophenolate in psoralen-UV-A desensitization therapy for chronic actinic dermatitis.
    Nousari HC; Anhalt GJ; Morison WL
    Arch Dermatol; 1999 Sep; 135(9):1128-9. PubMed ID: 10490129
    [No Abstract]   [Full Text] [Related]  

  • 84. A cure-rate model for Q-learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients.
    Moodie EEM; Stephens DA; Alam S; Zhang MJ; Logan B; Arora M; Spellman S; Krakow EF
    Biom J; 2019 Mar; 61(2):442-453. PubMed ID: 29766558
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Segmental stiff skin syndrome (SSS): Two additional cases with a positive response to mycophenolate mofetil and physical therapy.
    Kurtzman DJ; Wright NA; Patel M; Vleugels RA
    J Am Acad Dermatol; 2016 Dec; 75(6):e237-e239. PubMed ID: 27846975
    [No Abstract]   [Full Text] [Related]  

  • 86. The "drug vs graft-vs-host disease" conundrum gets tougher, but there is an answer: the challenge to dermatologists.
    Nghiem P
    Arch Dermatol; 2001 Jan; 137(1):75-6. PubMed ID: 11176664
    [No Abstract]   [Full Text] [Related]  

  • 87. Granulomatous Myositis as a Manifestation of Chronic Graft-Versus-Host Disease: A Case Series and Review of the Literature.
    Roy C; Lai EJ; Lee AHA; Schutz P; Maguire J; Toze CL; Nevill TJ; Abou Mourad YR
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e459-e462. PubMed ID: 35074288
    [No Abstract]   [Full Text] [Related]  

  • 88. Rituximab versus Mycophenolate Mofetil in Pemphigus Vulgaris.
    Hopkins ZH; Wu BC; Nousari CH
    N Engl J Med; 2021 Sep; 385(11):1055-1056. PubMed ID: 34496187
    [No Abstract]   [Full Text] [Related]  

  • 89. Rituximab versus Mycophenolate Mofetil in Pemphigus Vulgaris. Reply.
    Werth VP; Joly P; Chen DM
    N Engl J Med; 2021 Sep; 385(11):1056. PubMed ID: 34496188
    [No Abstract]   [Full Text] [Related]  

  • 90. Successful treatment of constrictive chronic pericarditis with mycophenolate sodium in a patient with systemic sclerosis.
    Fernández-Codina A; Francisco-Pascual J; Fonollosa-Plà V
    Med Clin (Barc); 2017 Jun; 148(12):574-575. PubMed ID: 28283274
    [No Abstract]   [Full Text] [Related]  

  • 91. [Chronic graft-versus-host disease].
    Dräger H; Kovnerystyy O; Ruzicka T; Stege H
    Hautarzt; 2005 Apr; 56(4):370-2. PubMed ID: 15750671
    [No Abstract]   [Full Text] [Related]  

  • 92. Improving Outcomes in Chronic Graft-vs-Host Disease.
    Mitchell SA; Cowen EW
    JAMA Dermatol; 2024 Apr; 160(4):388-391. PubMed ID: 38416464
    [No Abstract]   [Full Text] [Related]  

  • 93. What's behind chronic graft versus host disease incidence curves?
    Mussetti A; Sureda A
    Lancet Haematol; 2020 Feb; 7(2):e83-e84. PubMed ID: 31958418
    [No Abstract]   [Full Text] [Related]  

  • 94. [Treatment of chronic ocular graft versus host disease].
    Cheng XJ; Yuan RD; Zhang X
    Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):877-880. PubMed ID: 36709206
    [No Abstract]   [Full Text] [Related]  

  • 95. ROCKing Chronic Graft-Versus-Host Disease.
    Heine A; Holderried TAW; Wolf D
    J Clin Oncol; 2021 Oct; 39(29):3308. PubMed ID: 34347530
    [No Abstract]   [Full Text] [Related]  

  • 96. Prevalence of isolated joint involvement in chronic graft-versus-host disease: comment on the article by Inamoto et al.
    Kuzmina Z; Joe GO; Baird K; Cowen EW; Naik HB; Steinberg SM; Curtis L; Comis LE; Pavletic SZ
    Arthritis Rheumatol; 2014 Sep; 66(9):2646-8. PubMed ID: 24819543
    [No Abstract]   [Full Text] [Related]  

  • 97. [HDL therapy for acute graft-versus-host disease].
    Daguindau É; Chagué C; Saas P
    Med Sci (Paris); 2023 May; 39(5):418-421. PubMed ID: 37219345
    [No Abstract]   [Full Text] [Related]  

  • 98. Drug minimization in transplantation: an opinion.
    Waldmann H
    Curr Opin Organ Transplant; 2014 Aug; 19(4):331-3. PubMed ID: 24991978
    [No Abstract]   [Full Text] [Related]  

  • 99. Pseudo-Volkmann contracture as a complication of chronic graft-versus-host disease.
    Shakshouk H; Geissler JA; Hogan WJ; Rhodes NG; Lehman JS
    Dermatol Ther; 2021 Jan; 34(1):e14701. PubMed ID: 33368970
    [No Abstract]   [Full Text] [Related]  

  • 100. Thalidomide for graft-versus-host disease.
    Vogelsang GB; Santos GW; Colvin OM; Chen T
    Lancet; 1988 Apr; 1(8589):827. PubMed ID: 2895345
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.